Ischemia-modified albumin levels in threatened abortion and missed abortion compared to healthy pregnancies

Abstract

This study aims to investigate differences in serum ischemia-modified albumin (IMA) and adjusted IMA levels among cases of healthy intrauterin pregnancies, threatened abortions, and missed abortions. In this prospective case-control study, a total of 90 participants were included, distributed into three groups: missed abortion (n = 30), threatened abortion (n = 30), and intrauterin healthy pregnancy (n = 30). IMA and adjusted IMA values were calculated for each group. Our findings revealed no significant differences in serum IMA and adjusted IMA concentrations among the three groups. Additionally, there were no correlation observed between IMA levels, adjusted IMA levels, and maternal age, body mass index (BMI), white blood cell (WBC) count, neutrophil count, lymphocyte count, platelet count, neutrophil-to-lymphocyte ratio (NLR), platelet-to lymphocyte ratio (PLR), mean corpuscular volume (MCV), and red cell distribution width (RDW). The study concludes that IMA lacks a reliable capacity to differentiate between potential healthy intrauterine pregnancies, threatened abortions, or missed abortions during the first trimester. These results highlight the need for exploring alternative biomarkers that may offer greater specificity in distinguishing various pregnancy outcomes in early gestation.

Keywords

• Ischemia-modified albumin
• healthy pregnancy
• threatened abortion
• missed abortion
• early pregnancy

References

1. Loss EP. Acog Practıce Bulletın Summary. 2018 [cited 2023 Nov 21]; Available from: https://journals.lww.com/greenjournal/Fulltext/2018/11000/ACOG_Practice_Bulletin_No__200_Summary__Early.36.aspx
2. Magnus MC, Wilcox AJ, Morken NH, Weinberg CR, Håberg SE. Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study. bmj [Internet]. 2019 [cited 2023 Nov 26];364. Available from: https://www.bmj.com/content/364/bmj.l869.long
3. Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP, Canfield RE, et al. Incidence of Early Loss of Pregnancy. N Engl J Med. 1988 Jul 28;319(4):189–94.
4. Jauniaux E, Burton GJ. Pathophysiology of histological changes in early pregnancy loss. Placenta. 2005;26(2–3):114–23.
5. Alves C, Jenkins SM, Rapp A. Early Pregnancy Loss (Spontaneous Abortion). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Dec 1]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK560521/
6. Sivalingam VN, Duncan WC, Kirk E, Shephard LA, Horne AW. Diagnosis and management of ectopic pregnancy. Journal of family planning and reproductive health care. 2011;37(4):231–40.
7. Shaunik A, Kulp J, Appleby DH, Sammel MD, Barnhart KT. Utility of dilation and curettage in the diagnosis of pregnancy of unknown location. American journal of obstetrics and gynecology. 2011;204(2):130-e1.
8. Yücel D. Ischemia – modified albumin by albumin cobalt binding test: a false myth or reality. Turkish Journal of Biochemistry. 2023 Feb 1;48(1):1–4.

9. Guven S, Alver A, Mentese A, Ilhan FC, Calapoglu M, Unsal MA. The novel ischemia marker 'ischemia‐modified albumin' is increased in normal pregnancies. Acta Obstet Gynecol Scand. 2009 Apr;88(4):479–82.
10. Bahinipati J, Mohapatra PC. Ischemia modified albumin as a marker of oxidative stress in normal pregnancy. Journal of clinical and diagnostic research: JCDR. 2016;10(9):BC15.
11. Doğan K, Guraslan H, Çankaya A, Dağdeviren H, Ekin M. Ischemia-Modified Albumin (IMA): A Novel Marker for Preeclampsia Independent of Uterine Artery Notching Identified by Doppler Ultrasound. Hypertension in Pregnancy. 2015 Oct 2;34(4):516–24.
12. Karaşin SS, Çift T. The role of ischemia-modified albumin as a biomarker in preeclampsia. Revista Brasileira de Ginecologia e Obstetrícia. 2020;42:133–9.
13. Rossi A, Bortolotti N, Vescovo S, Romanello I, Forzano L, Londero AP, et al. Ischemia-modified albumin in pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2013;170(2):348–51.
14. Gölbaşı C, Gölbaşı H, Gültekin CK, Gülseren V, Akşit MZ, Bayraktar B, et al. Ischemia modified albumin levels in intrauterine growth restriction: levels are increased in fetal cord blood but not in maternal blood. Ginekologia Polska. 2022;93(12):993–8.
15. Hilali N, Aksoy N, Vural M, Camuzcuoglu H, Taskin A. Oxidative status and serum prolidase activity in tubal ectopic pregnancy. JPMA The Journal of the Pakistan Medical Association. 2013;63(2):169–72.
16. Duhig K, Chappell LC, Shennan AH. Oxidative stress in pregnancy and reproduction. Obstet Med. 2016 Sep;9(3):113–6.
17. Bar–Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report. The Journal of emergency medicine. 2000;19(4):311–5.
18. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischemia-modified albumin testing: adjustment for serum albumin. Clinical Chemical Laboratory Medicine [Internet]. 2007 Jan 1 [cited 2023 Nov 28];45(2). Available from: https://www.degruyter.com/document/doi/10.1515/CCLM.2007.039/html
19. Özdemir S, Kıyıcı A, Balci O, Göktepe H, Çiçekler H, Çelik Ç. Assessment of ischemia-modified albumin level in patients with recurrent pregnancy loss during the first trimester. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2011 Apr 1;155(2):209–12.
20. Cengiz H, Dagdeviren H, Kanawati A, Suzen Çaypinar S, Yesil A, Ekin M, et al. Ischemia-modified albumin as an oxidative stress biomarker in early pregnancy loss. J Matern Fetal Neonatal Med. 2016;29(11):1754–7.
21. Dogan K, Helvacioglu C, Baghaki S, Kural A, Dogan M. Ischemia-Modified Albumin (IMA) levels in ectopic pregnancy and early pregnancy loss. Niger J Clin Pract. 2022 Jul;25(7):975–8.
22. Ma SG, Wei CL, Hong B, Yu WN. Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease. Clinics. 2011;66:1677–80.
23. Saglam E, Sener G, Bayrak T, Bayrak A, Gorgulu N. Analysis of Ischemia-Modified Albumin (IMA) and Coagulation Parameters in Patients with SARS-CoV-2 Pneumonia. J Clin Med. 2023 Jun 27;12(13):4304.
24. Piva SJ, Duarte MM, Da Cruz IB, Coelho AC, Moreira APL, Tonello R, et al. Ischemia-modified albumin as an oxidative stress biomarker in obesity. Clinical biochemistry. 2011;44(4):345–7.
25. Mehmetoğlu İ, Kurban S, Yerlikaya FH, Polat H. Obesity Is an Independent Determinant of Ischemia-Modified Albumin. Obesity Facts. 2012 Oct 18;5(5):700–9.
26. Yigitbasi T, Baskin Y, Akgol E, Kocal GC, Ellidokuz H. Association of ischemia-modified albumin with oxidative stress status and insulin resistance in obese patients. Revista Romana de Medicina de Laborator. 2017 Jul 26;25(3):255–63.
27. Ulubas D, Kavurt AS, Aydemi̇r O, Baş AY, Demi̇rel N. Serum ischemia-modified albumin levels in neonatal sepsis and septic shock. Türk Kadın Sağlığı ve Neonatoloji Dergisi. 2020 Mar 30;2(1):7–12.
28. Uçkan K, Demir H, Demir C. Maternal serum ischemia-modified albumin (IMA), total-sulphydryl concentrations, and some subclinic inflammatory markers in hyperemesis gravidarum (HG). Taiwanese Journal of Obstetrics and Gynecology. 2023 Jan 1;62(1):101–6.